tiprankstipranks
Trending News
More News >
RedHill Biopharma Ltd (RDHL)
:RDHL

RedHill Biopharma (RDHL) AI Stock Analysis

Compare
840 Followers

Top Page

RD

RedHill Biopharma

(NASDAQ:RDHL)

Rating:41Neutral
Price Target:
$2.00
▼(-4.76%Downside)
The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.

RedHill Biopharma (RDHL) vs. SPDR S&P 500 ETF (SPY)

RedHill Biopharma Business Overview & Revenue Model

Company DescriptionRedHill Biopharma (RDHL) is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal and infectious diseases. The company is headquartered in Israel and operates primarily in the pharmaceutical sector, offering a range of products aimed at addressing significant medical needs in these areas.
How the Company Makes MoneyRedHill Biopharma makes money through the development, marketing, and sale of its proprietary drug formulations targeting gastrointestinal and infectious diseases. The company's revenue primarily comes from the commercialization of its core products, which include approved and marketed drugs as well as those in different stages of clinical development. Significant partnerships with other pharmaceutical companies may also contribute to its earnings, allowing for strategic collaborations in drug development and distribution. Revenue streams are further bolstered by licensing agreements and potential milestone payments associated with the advancement of its drug pipeline.

RedHill Biopharma Financial Statement Overview

Summary
RedHill Biopharma is facing significant financial challenges, with negative net profit margins and cash flow issues. The balance sheet reflects high leverage and financial distress, which are critical concerns.
Income Statement
40
Negative
The company's revenue has shown inconsistent growth with recent declines from previous highs. The gross profit margin has been relatively healthy, but the net profit margin is negative due to high EBIT losses, indicating challenges in managing costs effectively. There is a significant negative EBIT and EBITDA margin, reflecting operational inefficiencies.
Balance Sheet
30
Negative
The balance sheet reveals a concerning financial structure with negative stockholders' equity in recent years, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, suggesting high leverage and risk.
Cash Flow
35
Negative
Cash flow statements show negative operating and free cash flows, indicating cash burn and financial strain. Despite positive financing cash flows, the operating cash flow to net income and free cash flow to net income ratios are negative, pointing to insufficient cash generation from operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue35.74M8.04M6.51M61.80M85.76M64.36M
Gross Profit15.28M4.85M3.05M28.46M36.35M27.47M
EBITDA52.28M-7.59M26.27M-42.84M-63.03M-54.94M
Net Income-10.80M-8.27M23.92M-59.24M-114.31M-89.02M
Balance Sheet
Total Assets35.04M18.04M23.05M158.87M181.19M180.24M
Cash, Cash Equivalents and Short-Term Investments7.01M4.62M6.36M19.98M38.00M29.79M
Total Debt2.28M356.00K1.17M122.69M87.81M86.90M
Total Liabilities31.57M22.73M20.98M207.27M172.31M166.38M
Stockholders Equity3.47M-4.68M2.07M-48.40M8.88M13.86M
Cash Flow
Free Cash Flow-23.83M-9.38M-35.83M-29.38M-65.16M-102.35M
Operating Cash Flow-26.22M-9.37M-35.82M-29.18M-65.05M-48.58M
Investing Cash Flow-8.53M-9.00K8.30M-8.14M-35.65M
Financing Cash Flow6.29M8.42M21.38M11.45M73.46M84.37M

RedHill Biopharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.10
Price Trends
50DMA
1.94
Positive
100DMA
2.54
Negative
200DMA
4.95
Negative
Market Momentum
MACD
0.02
Negative
RSI
61.26
Neutral
STOCH
92.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDHL, the sentiment is Neutral. The current price of 2.1 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.94, and below the 200-day MA of 4.95, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.26 is Neutral, neither overbought nor oversold. The STOCH value of 92.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RDHL.

RedHill Biopharma Risk Analysis

RedHill Biopharma disclosed 86 risk factors in its most recent earnings report. RedHill Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

RedHill Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
NBNBY
45
Neutral
$3.86M-235.50%-49.76%96.81%
41
Neutral
$4.72M1155.92%
34
Underperform
$2.88M-129.08%9.41%
31
Underperform
$14.62M270.52%85.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RDHL
RedHill Biopharma
2.10
-6.79
-76.38%
NBY
NovaBay Pharma
0.66
-1.64
-71.30%
MBIO
Mustang Bio
2.66
-19.34
-87.91%
PRFX
PainReform
1.40
-10.17
-87.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025